Association between NICE guidance on biologic therapies with rates of hip and knee replacement among rheumatoid arthritis patients in England and Wales:An interrupted time-series analysis. by Hawley, S. et al.
                          Hawley, S., Cordtz, R., Dreyer, L., Edwards, C. J., Arden, N. K., Delmestri,
A., ... Prieto-Alhambra, D. (2018). Association between NICE guidance on
biologic therapies with rates of hip and knee replacement among rheumatoid
arthritis patients in England and Wales: An interrupted time-series analysis.
Seminars in Arthritis and Rheumatism, 47(5), 605-610.
https://doi.org/10.1016/j.semarthrit.2017.09.006
Publisher's PDF, also known as Version of record
License (if available):
CC BY-NC-ND
Link to published version (if available):
10.1016/j.semarthrit.2017.09.006
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Elsevier at
https://www.sciencedirect.com/science/article/pii/S0049017217303104. Please refer to any applicable terms of
use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms




E-mjournal homepage: www.elsevier.com/locate/semarthritAssociation between NICE guidance on biologic therapies with rates of
hip and knee replacement among rheumatoid arthritis patients in
England and Wales: An interrupted time-series analysis
Samuel Hawley, MSca, René Cordtz, MDc,d, Lene Dreyer, MDc,d,
Christopher J. Edwards, MDe,f, Nigel K. Arden, MDb,g, Antonella Delmestri, PhDb,
Alan Silman, MDb, Cyrus Cooper, MDb,f, Andrew Judge, PhDb,f,
Daniel Prieto-Alhambra, MD, PhDa,h,n
aCentre for Statistics in Medicine, Nufﬁeld Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre,
University of Oxford, Windmill Road, Oxford, OX3 7LD
bNufﬁeld Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Windmill Road,
Oxford OX3 7LD, UK
cCentre for Rheumatology and Spine Diseases, Gentofte University Hospital, Rigshospitalet, Copenhagen, Denmark
dThe Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
eUniversity Hospital Southampton NHS Foundation Trust, Southampton, UK
fMusculoskeletal Research Unit, NIHR Wellcome Trust Clinical Research Facility, University of Southampton, Southampton, UK
gMRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK
hGREMPAL Research Group, Idiap Jordi Gol Primary Care Research Institute and CIBERFes, Universitat Autònoma de Barcelona and Instituto de Salud Carlos







72/& 2018 The Authors. Published by Elsevie
reativecommons.org/licenses/by-nc-nd/4.0/).
esponding author.
ail address: daniel.prietoalhambra@ndorms.oxa b s t r a c t
Objective: To estimate the impact of NICE approval of tumor necrosis factor inhibitor (TNFi) therapies on
the incidence of total hip replacement (THR) and total knee replacement (TKR) among rheumatoid
arthritis (RA) patients in England and Wales.
Methods: Primary care data [Clinical Practice Research Datalink (CPRD)] for the study period
(1995–2014) were used to identify incident adult RA patients. The age and sex-standardised 5-year
incidence of THR and TKR was calculated separately for RA patients diagnosed in each six-months between
1995–2009. We took a natural experimental approach, using segmented linear regression to estimate
changes in level and trend following the publication of NICE TA 36 in March 2002, incorporating a 1-year
lag. Regression coefﬁcients were used to calculate average change in rates, adjusted for prior level and trend.
Results: We identiﬁed 17,505 incident RA patients of whom 465 and 650 underwent THR and TKR surgery,
respectively. The modeled average incidence of THR and TKR over the biologic-era was 6.57/1000 person
years (PYs) and 8.51/1000 PYs, respectively, with projected (had pre-NICE TA 36 level and trend continued
uninterrupted) ﬁgures of 5.63/1000 PYs and 12.92 PYs, respectively. NICE guidance was associated with a
signiﬁcant average decrease in TKR incidence of −4.41/1000 PYs (95% C.I. −6.88 to −1.94), equating to a
relative 34% reduction. Overall, no effect was seen on THR rates.
Conclusions: Among incident RA patients in England and Wales, NICE guidance on TNFi therapies for RA
management was temporally associated with reduced rates of TKR but not THR.
& 2018 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Key messages
— In England and Wales, TNFi approval for RA was associated
with reduced TKR rates.
— In England and Wales, no change in THR rates was seen
following TNFi approval.r HS Journals, Inc. This is an open
.ac.uk (D. Prieto-Alhambra).— Further studies in non-UK settings are required to validate
these ﬁndings.accesIntroduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease
associated with pain, stiffness and swelling in affected joints [1].
Joint damage is a central feature of RA [2], estimated to account fors article under the CC BY-NC-ND license
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from the mid-late 20th century indicate that over half of incident
RA patients required RA-related surgery over 30 years of follow-up
[4]. Despite some evidence suggesting that joint erosions can heal
over time [3], such healing is generally rare [5] and reducing the
risk of irreversible joint damage through early and ‘treat-to-target'
disease management is emphasized in numerous guidelines.
The literature widely recognizes that the availability of biological
disease modifying anti-rheumatic drugs (bDMARDs) over recent
decades has revolutionised the management of RA [6–8]. A wealth
of randomized controlled trial (RCT) data has conclusively demon-
strated the beneﬁcial impact of bDMARDs on ACR response criteria
and structural joint damage [8,9]. However, no such data exists
concerning the impact of bDMARDs on the need for joint replace-
ment—a costly consequence of joint failure that is not without its risks.
During the “biologic era” there has been an emerging body of
observational studies indicating that the number and/or incidence of
RA-related joint surgery has generally been decreasing across numer-
ous developed countries [10–20]. Although the use of biologic
therapies has been routinely offered as an explanatory factor, their
role is not clear and estimation of their impact on the incidence of
joint replacement remains lacking.
It has previously been suggested that when an RCT is likely to be
unfeasible, a strong research alternative is to take advantage of
naturally occurring events such as a national health policy change
in order to carry out a quasi-experiment [21]. In this context, our aim
was to estimate the impact of the national institute for health and
care excellence (NICE) approval of tumor necrosis factor inhibitor
(TNFi) therapy [22] on the temporal trends of total hip (THR) and total
knee replacement (TKR) among RA patients in England and Wales.Methods
Study population and data sources
We used primary care health data from the Clinical Practice
Research Datalink (CPRD) for the period Apr 1995 to Sept 2014. As
of 2013, CPRD covered over 11.3 million patients from 674 UK practices
and had a representative coverage of approximately 7% of the United
Kingdom [23]. Where available, we obtained linked secondary care
Hospital Episode Statistics (HES) data for the same time period.
Approximately 58% of UK CPRD practices participate in the CPRD
linkage scheme [23] and previous research by CPRD has shown that
linked practices/patients are representative of the CPRD population as
a whole. HES data contains hospital admission records relating to each
‘ﬁnished consultant episode’—the period of time an individual spends
under the care of one NHS consultant. Mortality data were linked to
the Ofﬁce for National Statistics (ONS) database.
Incident RA patients within the study period were identiﬁed using
a pre-deﬁned READ code list (Appendix Table 1), as developed
elsewhere [24], with the date of ﬁrst recorded RA considered as
diagnosis date. Data on BMI, smoking status and Charlson comorbidity
score at date of RA diagnosis was also extracted from CPRD. Patients
with either a prior or subsequent diagnosis of a different inﬂammatory
arthritis (lupus, ankylosing spondylitis, psoriatic arthritis or crystal
arthropathy) were excluded due to possible diagnosis or coding errors.
Patients aged o18 years old were also excluded as were patients
registered in a general practitioner (GP) practice outside England or
Wales given that compliance to NICE guidance is only mandatory for
these countries (Appendix Fig. 1).
Intervention
Our deﬁned intervention was the publication of the NICE
technology appraisal (TA) 36 in March 2002. This providedguidance on the use of TNFi (etanercept and inﬂiximab) for the
treatment of RA, and stated that these therapies were recom-
mended options for the treatment of adults with severe RA
(Disease Activity Score (DAS) 45.1) who had already failed to
respond to two conventional synthetic disease modifying anti-
rheumatic drug (csDMARD) therapies.
Outcomes
We used CPRD Read codes as used previously [25,26] to identify
the occurrence of ﬁrst THR and TKR after incident RA diagnosis.
THR and TKR were considered separately so patients could
potentially have both outcomes of interest. For validation pur-
poses, we also identiﬁed ﬁrst subsequent THR and TKR within the
HES data using the classiﬁcation of interventions and procedures
coding system (OPCS4). Reporting of THR and TKR in HES has
previously been shown to be comparable with the National Joint
Registry (NJR) [27].
Statistical analysis
To assess the validity of the THR and TKR Read codes, we
calculated sensitivity and speciﬁcity among the 62.6% of RA patients
with both CPRD and HES data (Appendix Fig. 1), considering HES as
the reference standard. Agreement was deﬁned as surgeries present
in both data sources within a 60-day time period, with 30-day and
90-day time periods also explored. Given that good agreement was
found (Appendix Table 2), we proceeded to use THR and TKR as
reported in CPRD for the main analysis, and the whole study
population (including those with no linked HES) were included.
An age and sex standardised time-series was derived by
calculating 5-year incidence rates of THR and TKR among newly
diagnosed RA patients within each 6 months between 1995 and
2009. We only concentrated on the ﬁrst 5 years after diagnosis so
that patients contributed the same follow-up irrespective of when
they were diagnosed to allow valid rate comparisons throughout
the study period. Patients were followed up from date of diagnosis
until the ﬁrst date of: outcome event, death, loss to follow-up or
5 years of follow-up.
A segmented linear regression was performed on the aggre-
gated standardised time-series to estimate two parameters of
interest associated with the publication of NICE TA 36: change in
subsequent level of outcome and change in subsequent trend [28].
Given that the NICE guidance recommended that only patients
having a failed response to two (6 month) trials of csDMARD
therapy should initiate a TNFi, a 1-year lag period following March
2002 was decided upon a-priori in which data were removed from
the time-series. The regression model was speciﬁed as following:
Yt ¼ β0 þ β1 n timet þ β2 n interventiont þ β3 n post_interven-
tion_timet þ et. Here, Yt is the 5-year incidence among RA patients
diagnosed at time point (i.e., 6-monthly period) t. β0 estimates the
baseline level of the outcome just before the beginning of the time
series. β1 estimates the pre-intervention trend, β2 the change in
level between the time point immediately before vs. after the lag
period and β3 the change in trend occurring immediately after the
lag period. Analyses were based on 14 pre-intervention data points
(Apr 1995–Mar 2002) and 13 post-intervention data points
(Apr 2003–Sept 2009). Final model speciﬁcation was derived using
a backward-stepwise approach (p-entry 0.049; p-exit 0.20) to
remove non-signiﬁcant regression terms in order to maximize
statistical power, although results from full models were also
reported. Durbin-Watson statistics indicated no signiﬁcant
autocorrelation.
Regression coefﬁcients were used to estimate an overall inter-
vention effect by predicting what would have been observed post-
intervention (i.e., counterfactual rates) had pre-intervention levels
Table 1
Temporal trends in joint replacement rates among 17,505 incident rheumatoid
arthritis patients diagnosed from 1995 to 2009 (per 1000 person-years)
Lower Upper
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what was modeled using observed post-intervention data [28,29].
The midpoint of the post-intervention period was used to calculate
the average difference over the post-intervention time points.Parameter Coefﬁcient 95% CI 95% CI p value
Total hip replacement
Intercept 5.63 4.73 6.52 o0.001
Trenda – – – –
Level change after NICE TA 36 3.97 1.79 6.14 0.001
Trend change after NICE TA 36a −0.47 −0.71 −0.22 0.001
Total knee replacement
Intercept 5.89 3.83 7.94 o0.001
Trenda 0.31 0.11 0.51 0.004
Level change after NICE TA 36 – – – –
Trend change after NICE TA 36a −0.68 −1.08 −0.28 0.002
– ¼ p ≥ 0.2.
a per 6 months.Sensitivity analyses
Due to likely delay in implementation of NICE recommenda-
tions, a 2-year lag period was used in a sensitivity analysis. A data-
driven (with no pre-speciﬁed time point/intervention) approach
was also conducted using a Joinpoint analysis in order to identify
where—if at all—any changes in trend occurred [30]. An uncorre-
lated errors model was speciﬁed, using the grid search method
with a maximum of one Joinpoint and minimum of eight obser-
vations before and after (as recommended for an interrupted time
series approach). Model selection was carried out using permuta-
tion tests (Monte Carlo methods) with a signiﬁcance level set to
0.05.Results
Between 1995 and 2014 there were 23,830 incident RA patients
identiﬁed, of whom 10,952 had HES linkage (Appendix Fig. 1).
Considering HES as the reference standard, THR in CPRD had 80.1%
sensitivity and 98.4% speciﬁcity whilst TKR in CPRD had 83.5%
sensitivity and 98.1% speciﬁcity (Appendix Table 2).
Included in the interrupted time series analysis were 17,505
incident RA patients diagnosed in CPRD between 1995 and 2009
(Appendix Fig. 1). Patient characteristics are presented in
Appendix Table 3. Mean age at RA diagnosis increased slightly
from 58.7 in 1995 to 60.3 in 1999 (p ¼ 0.065), whilst the gender
ratio remained fairly stable over the same time frame (70.4% to
66.3% female; p ¼ 0.12). Prevalence of obesity (BMI ≥ 30), as
reported at time of RA diagnosis, increased from 11.5% in 1995 to
22.1% in 2009 (p ≤ 0.001), whilst concurrent smoking status
decreased from 27.9% to 20.9% (p ¼ 0.011). Overall there were
465 THRs and 650 TKRs occurring within 5 years of RA diagnosis
(Fig. 1), yielding a crude incidence rate of 6.16/1000 person years
(PYs) (95% CI: 5.63–6.75) and 8.65/1000 PYs (95% CI: 8.01–9.34),
respectively. Median follow-up over the 5 years following RA
diagnosis was 5.00 years (inter quartile range (IQR): 3.69–5.00)
for THR and 5.00 years (IQR: 3.60–5.00) for TKR, with median
time-to-event being 1.96 (IQR: 0.95–3.24) and 2.32 (IQR: 1.02–
3.58), respectively. Average mortality over the same time frame
was 15.5% while loss-to-follow-up was 18.2%.Fig. 1. Number of RA patients undergoing THR/TKR surgery within 5 years:
stratiﬁed by year.Age and sex standardised 5-year incidence of THR at the start of
the study period was 5.63/1000 PYs (95% CI: 4.74–6.54), which
remained unchanged during the pre-TNFi period (Apr 1995–Mar
2002) (Table 1 and Fig. 2A). Immediately following the interven-
tion lag period there was a level increase in the incidence rate by
3.97/1000 PYs (95% CI: 1.79–6.14) but a subsequent downward
trend of −0.47/1000 PYs (95% CI: −0.71–0.22) per 6 months for the
remainder of the post-NICE TA36 time period. Based on these
coefﬁcients, the estimated incidence of THR at the mid-point of the
post-NICE TA36 time period was 6.57/1000 person years (PYs). The
incidence at the same time point estimated solely by extrapolating
the pre-NICE TA36 level and trend was 5.63/1000 PYs, therefore
translating to no signiﬁcant average change in rates (0.95/1000 PYs
(95% CI: −2.66 to 4.56)).
The incidence of TKR was 5.89/1000 PYs (95% CI: 3.83– 7.94) at
the start of the study period, which increased by 0.31/1000 PYs
(95% CI: 0.11 – 0.51) per 6 months during the pre-intervention
period (Table 1 and Fig. 2B). Immediately following the 1-year lag
period there was a signiﬁcant downward change in the prior
upward trend by −0.68/1000 PYs (95% CI: −1.08 to −0.28) per
6 months. Based on these coefﬁcients the modeled incidence for
the midpoint of the post-intervention period was 8.51/1000 PYs,
which was a signiﬁcant 4.41/1000 PYs (95% CI: 6.88–1.98) lower
compared to that estimated, had pre-intervention trends contin-
ued uninterrupted (Table 2). This equated to an approximate
relative 34% reduction.
In sensitivity analyses using a 2-year lag, THR rates remained
ﬂat during the study period while results for TKR remained
unchanged from the main analysis (Appendix Fig. 2). Conversely,
Joinpoint analysis identiﬁed signiﬁcant inﬂections in upward
trends in the incidence of both THR and TKR, at the time points
spanning Oct 2005–Mar 2006 (P ¼ 0.034) and Apr 2001–Sep 2001
(P ¼ 0.036), respectively. Results from the main analysis using full
models were unchanged as when using parsimonious models
(Appendix Table 4).Discussion
Our results indicate that the introduction of TNFi therapies for
the management of RA was associated with a signiﬁcant reduction
in TKR but not THR incidence among early RA patients within
England and Wales. Speciﬁcally, whilst TKR incidence was increas-
ing prior to TNFi approval, this upward trend was reversed
following the start of the biologic era, yielding a relative 34%
average reduction compared to counterfactual rates. The relation-
ship between THR incidence and TNFi approval was less clear, with
Fig. 2. Standardised incidence of joint replacement within 5 years: (A) THR and
(B) TKR.
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compared to counterfactual values.
Treatments recommended by a NICE TA publication “as an
option” should be available for use in the NHS within 3 months of
the guidance being published [31]. Although in reality this may not
be the case for a particular patient due to delayed implementation
at a local level, a population-level increase in the use of etanercept
and inﬂiximab (in line with the recommendations) would be
expected [32,33] given the authoritative and widespread reach of
NICE.
The potential impact of TNFi therapy on need for joint replace-
ment was not mentioned in the NICE TA 36 document, although
the evidence base referred to indicates the plausibility of such aTable 2
Estimated difference (per 1000 person years) in joint replacement rates following













5.63 6.57 0.95 −2.66 4.56
Total knee
replacement
12.92 8.51 −4.41 −6.88 −1.94
aPost-NICE TA 36 midpoint estimate (June 2006).
bCalculated by comparing estimated values for midpoint of post-intervention
period to counterfactual values for the same time point (i.e., post-intervention
midpoint values estimated based solely on extrapolation of pre-intervention level
and/or trend). Estimated from parsimonious models.relationship. For example, results from a high quality RCT were
summarized, in which 31% of patients on methotrexate alone
experienced progression of structural damage at 54 weeks, whilst
this was only 8% for patients on methotrexate plus inﬂiximab [22].
Indeed, the clinical effectiveness of both these therapies in terms
of reduced erosive damage is well established [34–36] and joint
replacement has been suggested as an important consideration in
future economic modeling of the management of RA with
bDMARDs [8,37].
Our decrease in TKR rates is consistent with data from the UK
NJR which indicate the percentage of knee replacements for which
RA was an indication fell from 3% to 2% (2004–2010) [10,38]. Our
data also complements and builds on prior studies from elsewhere
in Europe and the US. Notably, in the Republic of Ireland the
number of THR and TKR surgeries was found to increase dramat-
ically from 1995 to 2010, whilst the number of those with a
diagnosis of RA signiﬁcantly decreased for TKR but remained
stable for THR [18]. A similar study from the US found signiﬁcant
reductions in the number of both TKR and THR patients who had
RA as the primary diagnosis at surgery, whilst the numbers of TKR
and THR for other reasons profoundly increased [16]. Similar
arthroplasty trends were reported in most (Norway [39] and
Finland [13]) but not all (Sweden [19]) Scandinavian countries.
We found the overall incidence of THR to be lower than TKR,
which is supportive of milder RA involvement at the hip [40] and
which may explain why TNFi approval was here associated with
reduced rates of TKR but not THR. Previous estimates of hip joint
synovitis in early RA range between approximately 20% and 40%
[41,42], which is considerably lower than the 60% estimated for
the knee [43]. Also worth mentioning is that while the knee joint
featured in the 1987 ACR classiﬁcation criteria and Disease Activity
Score 28, the hip joint did not [44,45].
However, our lack of access to joint replacement rates for the
general population is a key limitation to our study. As such we
recognize the need for caution in interpreting our ﬁndings. For
example, it may be that the approximately stable incidence of THR
we observed for RA patients may be a favorable outcome were THR
incidence in the general population to have undergone a signiﬁ-
cant concurrent increase. Indeed, previous NJR data for the general
population indicate an overall year-on-year increase in the raw
number of both THR and TKR procedures carried out from 2003 to
2012 [46].
Furthermore, in evaluating the impact of NICE guidance on
biologics, we cannot rule out other factors such as prescription
rates of csDMARDs having markedly increased within this pop-
ulation [47], which may have contributed to a reduced need for
joint replacement [48]. Improvement in non-therapeutic aspects
of RA management and increased awareness may likewise have
played a role [49], as may a gradually declining disease severity or
changes in smoking prevalence or BMI, although we consider
these reasons insufﬁcient to explain the relatively sudden inﬂec-
tion observed in the TKR trend following NICE recommendations
[50]. Another intriguing possibility is that the mere availability of
bDMARDS may have given rise to a greater impetus among
clinicians to diagnose RA earlier in its natural history, and thereby
contributed to a decline in 5-year TKR rates. Whilst unfortunately
we do not have data on disease severity, we found the average
comorbidity index to worsen over the study period and there was
no evidence for a boom in incident RA diagnoses associated with
the advent of biologics (Appendix Table 3). It is also reassuring that
the annual proportion of RA patients migrating out of the CPRD
remained below 5% for all the years under study.
Related to this point is that etanercept and inﬂiximab prescrip-
tions are not administered or captured in the primary care setting
and were therefore not available for analysis. Whilst anecdotally
the speed and intensity of therapy uptake was subject to regional
S. Hawley et al. / Seminars in Arthritis and Rheumatism 47 (2018) 605–610 609variation, it's been previously reported that by 2005 approximately
8500 RA patients on TNFi had been recruited to the British Society
for Rheumatology Biologics Register (BSRBR-RA) [51]. For this
reason we used a 2-year lag as a sensitivity analysis to allow for
delayed implementation, which remained consistent with the
overall ﬁnding of reduced incidence of TKR but not THR in the
biologic era. The use of Joinpoint regression indicated a downward
inﬂection was best-placed at the time point 6–12 months prior to
NICE TA 36. This may suggest some role for the 2001 British
Society for Rheumatology guidelines (uponwhich NICE TA 36 were
based), although given the close temporal proximity this cannot be
determined.
The trend change in THR rates as identiﬁed in the Joinpoint analysis
was not consistent with the main analysis and was likely the product
of particularly low values for the last two time points (Fig. 2A). This
ﬁnding warrants further investigation regarding these methods,
notably the sensitivity to the number of time points in pre- vs. post-
intervention periods and the number of outcome events occurring per
time point. We are currently exploring these issues with the use of
simulated data. Further work will also include estimating the impact of
TNFi therapies using healthcare data outside the UK with the inclusion
of a non-RA control group.
Another caveat to our results is that they pertain to joint
replacements within the ﬁrst 5 years after RA diagnosis and so it
is possible we have underestimated the impact of TNFi therapy by
not considering longer-term outcomes. A ﬁxed 5-year time win-
dow across the study period was used to prevent THR and TKR
rates over time being inﬂuenced by underlying variation in the
length of follow-up available (i.e., the bias of patients at the
beginning of the study period systematically having longer enroll-
ment in the database).
Our study also has several strengths. We studied a large sample of
RA patients identiﬁed from a data source generalizable to the UK
population in terms of age, sex, and ethnicity [23]. Rather than
describing temporal trends of RA as an indicator for THR/TKR surgery,
we consider our approach of using RA patients as the denominator to
be preferable because this accounts for underlying changes in the
incidence of RA over time. The interrupted time-series analysis is
another strength as this quasi-experimental method controls for
secular trends in the outcome prior to the intervention [21,28], and
allows for comparison with counterfactual values. The importance of
this approach is evident given that a conventional before–after
comparison of time-to-TKR using a Cox regression model would have
here masked the positive association and yielded no signiﬁcant
difference as there are two almost equal but opposite trends in
existence (Fig. 2B). The linkage to HES allowed us to carry out an
internal validation of CPRD coding of THR and TKR, which we also
supplemented by estimating the 5- and 10-year cumulative incidence
of a combined THR/TKR outcome (results not shown) that were very
similar to reports from previous UK early RA inception cohorts, at
approximately 7% and 12%, respectively.
In conclusion, we have demonstrated that approval of TNFi
therapies in England and Wales was temporally associated with a
signiﬁcant and clinically meaningful decline in TKR incidence but
no change in THR incidence among early (ﬁrst 5 years post-
diagnosis) RA patients.Acknowledgments
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